It is still very difficult to explain the mechanism of this phenomenon. The gradient does not form during the freezing process, because the yellow color of a frozen serum appears homogeneous when viewed in crosssection or longitudinally.
thawing cannot be explained merely by relative density or freezing-point decrease, because all components have the same relative concentration in any fraction, from the top to the bottom, regardless of their relative density, the concentration of the molecule, or the solubility of serum components (Table 1 , Figures 1 and 3) . When we floated a block of frozen serum on water, the solubi.
lized serum sank, showing a streaming double refraction. Thawing of frozen serum actually started at the surface, but in the final stage, the frozen material became colorless and looked like pure ice. It seems that serum components from frozen material are selectively soluble, leaving behind ice particles. The net result is a dilution in the upper part and a concentration in the lower part of the serum. This explains why condensed (more concentrated) serum will sink during centrifugation, making the gradient slope steeper (Figure 3 ). Upon thawing during centrifugation, the slope of the gradient does not depend on the thawing temperature, suggesting that centrifugal force overcomes diffusion of the molecules and thermal convection of the liquid. However, we have no reasonable answer at present for why the original concentration is always found between fractions six and seven, i.e., at the same point under various centrifugal forces (Figure 3 ). We point out that, in the gradient formation of cesium chloride under
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ultracentrifugation, the original concentration was observed in the middle fraction as well (2, 3) .
Although the precise mechanism has not been clarified, a serum highly concentrated by freezing and thawing is extremely useful for routine work in clinical laboratories, e.g., for checking the linearity of a standard curve in a wide range of concentrations. In addition, the concentration ratios were the same for all serum components tested, without exception (Table 1, Figure 1 , and Figure 3 , bottom), so we do not need to prepare a fortified serum or obtain an abnormal serum for every component. This To help solve these problems, we adapted and modified the method of Kasidas and Rose (9) . In the urine assay, the pH is kept 3.5 and the ascorbate content is stabilized by conversion to dehydroascorbate with sodium nitrite. We improved the sensitivity of the method by using more-stable and more-sensitive instrumentation, so that the range of oxalate concentrations in normal plasma can be measured easily. We studied conditions for sample handling as related to stability of samples and ascorbate interference. We established normal reference intervals for oxalate concentrations in urine and plasma and, using a series of urine samples, 
PrIncIple
In (9) , and the reagents are the same as they used.
Materials and Methods

Procedures
We modified the original method of Kasidas and Rose and used different instrumentation.
The solid-state circuitry in the HPLC detector stabilizes the baseline and allows for an increased sensitivity of several magnitudes. The lower limit of detection in standard spectrophotometers is 0.01 absorbance unit (A), whereas the combination of instruments we used has a lower limit of 0.00001 A, a 1000-fold increase in sensitivity. The Kasidas and Rose procedure (9) voiding, were placed in a container with 10 mL of 10 mol/L HC1. The B aliquots were kept in a container with no preservative, stored at room temperature, and acidified with 10 mL of 10 mol/L HC1 within 2 h of the completion of the 24-h collection. The A and B aliquots, separately, were then mixed thoroughly and an aliquot of each was prepared for analysis or storage. The pH of all samples was <2.0.
Both of
Oxalate was measured initially on the day the collections were completed. Pre-acidified (A) urines from five of the apparently healthy subjects were divided into 36 aliquots for studies of time and temperature stability.
We stored 12 aliquots of each sample at room temperature (24 #{176}C), refrigerated (4#{176}C), and frozen (-20 #{176}C). Aliquots were analyzed daily on days 1-7 and again on days 14, 28, 64, and 190 after collection. To evaluate any interference by ascorbate in our samples, we collected a second 24-h urine sample from 10 of the apparently healthy subjects during a day in which they took 2 g (0.5 g four times) of ascorbic acid. These samples were divided into pro-acidified and postacidified aliquots, as outlined above. The 10 samples were assayed without delay, and again after 90 days of storage at pH <2.0 and -20 #{176}C to establish whether any in vitro false increases in oxalate production had occurred. All frozen samples were thawed at 60#{176}C for 10 miii before analysis. Stored samples were also measured by the method of Olthius et al. (5) . In addition to the conversion of ascorbate to oxalate, ascorbate can cause other problems for oxalate determination.
As a reducing agent, ascorbate can decrease the quantity of oxalate measured by decreasing the oxidation of the dye. Kasidas and Rose (9) showed that the use of sodium nitrite avoids the latter interference by converting ascorbate to dehydroascorbate, which does not interfere. We compared results of the oxalate oxidase enzyme Age,years Model 4000 (Dionex Corp. Itasca, IL) with an AS4AG guard column and an AS4A separation column. The buffer system was 2.8 mmolJL Na2CO3 and 2.2 mmol/L NaHCO3, pH 9.5, pumped at 2 mLlmmn. An AMMS suppressor was in-line before the conductivity detector, which was set at 3 zS. A Model 4270 integrator was used for quantification.
Plasma Samples and Assay
Normal reference intervals for plasma oxalate were established in 21 adults ( 
Results
Unne Oxalate
Mean oxalate recovery from urine samples was 95 (SD 4.4)%. The normal reference range for urine oxalate by the enzymatic method is 0.11-0.46 mmol/24 h (mean 0.238), or 10-40.5 mg/24 h (1 mmol = 88 mg), based on the mean (± 2 SD) of 99 normal subjects. The effect of subject age on the reference range was minimpl ( Figure  2) . Figure 3 shows Figure 6 shows that ingestion of ascorbate (2 g daily) had no significant effect on 24-h oxalate excretion in 10 normal subjects when measured on the day of collection. The mean oxalate was 0.25 mmol/24 h before ascorbate and 0.23 mmol/24 h while taking ascorbate. However, mean value for oxalate concentration as determined by the method of Olthius et al. (5) was 40% greater than that by the enzyme method (Figure 4) .
Plasma Oxalate
The mean concentration of plasma oxalate in 21 normal subjects was 2.5 (SD 0.7) moI/L. There was no difference (P = 0.1) between men (mean 2.8 imol/L, SD 0.7) and women (mean 2.3 mol/L, SD 0.7). The repeat value from the filtrates after storage for two to three months at -20 #{176}C was 2.2 zmol/L (SD 0.8), which is unchanged(P=
0.1).
Analytical recovery of unlabeled oxalate (2.5 izmol/L) added to the ifitrate was 87 (SD 9)%. Recovery of ['4C1-oxalate through the Centriflo cones was significantly greater at endogenous pH and at pHi and 2 than at pH 2.5, 3.5, and 5 ( Figure 7) . The pH of our samples was 1.77 and recovery of '4C was 86 (SD 10)%. Because ascorbate converts to oxalate at pH >4, we decreased the pH to between 1.5 and 2.0 until ultrafiltrates were obtained, to ensure maTinifil recovery, and maintained the pH <4 throughout the remainder of the assay and during storage. 
Urine
Our reference values for oxalate in urine by this method agree with those published by Kasidas and Rose (9) and are lower than the data reported with the method of Olthius et a!. (5) . Reference values in the literature range up to 50 mg/24 h, although the ascorbate-to-oxalate conversion was not clearly considered in some previously reported reference value studies. By our methods, the upper limit of normal is 0.46 mmol/24 h, or 40.5 mg/24 h. however, oxalate concentrations increased with long-term storage (90 days) even when acidified and frozen at -20 #{176}C.
Our data suggest the possibility that the previously reported increase in urinary oxalate in patients taking vitamin C is merely a product of ascorbate conversion in the urine container or during assay; thus, ascorbate may not be a risk factor for stone disease. Our data showed no oxalate increase in normal volunteers taking ascorbate, whether urine was acidified during or immediately after collection if assayed fresh. In fact, the oxalate concentrations were 4% less in the post-acidified samples than in the samples collected directly into HC1, so perhaps we did not get all of the precipitated oxalate back into solution in the post-acidified samples (oxalate precipitates easily in nonacidifled urine and is known to be difficult to get back into solution). It is also possible that some autoconversion of endogenous ascorbate to oxalate occurs in vivo in the urinary tract, so that normal values for urinary oxalate may include some converted ascorbate; however, this seems unlikely from our data because we did not see any difference in the pre-and post-ascorbate samples, even if they were acidified after collection.
For this method, collection and analysis of 24-h urine samples for oxalate are valid if the following guidelines are used:
#{149} Have subjects avoid ingestion of vitamin C supplements for 48 h before and during collection, to prevent autoconversion of ascorbate to oxalate during storage.
#{149} Use 10 mL of 10 mol/L HC1 to keep urine pH <2.0 during collection or immediately after collection toprevent precipitation of oxalate as well as autoconversion of ascorbate to oxalate; samples thus collected are stable when stored at room temperature, or refrigerated for up to 14 days, or frozen for up to six months. #{149} Thaw frozen samples at 60#{176}C for 10 mm. #{149} Centrifuge samples at 1000 x g for 2 min.
#{149} Analyze
within two weeks any samples from patients taking vitamin C because long-term storage allows conversion of exogenous ascorbate to oxalate in all storage methods studied. #{149} Avoid metal containers or caps and nitric acid as a preservative.
Plasma
This method is also sensitive enough to measure oxalate in the normal plasma range. Our plasma results of 2.5 imol/L in healthy subjects agree with GC and isotope dilution techniques (13, 14) . We changed the conditions for filtering plasma samples because our data showed poor recoveries of oxalate through the Centriflo cones at the pHs used by Kasidas and Rose (12) . The 86% recovery we obtained is quite acceptable, but corrections could be made by using isotopes. Recovery of oxalate added to filtrates was also acceptable, and stability was good in filtrates stored at pH 3.5-4.0 at -20 #{176}C for the two to three months tested.
